<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02433587</url>
  </required_header>
  <id_info>
    <org_study_id>08-14-29</org_study_id>
    <nct_id>NCT02433587</nct_id>
  </id_info>
  <brief_title>Evaluation of Short Versus Long Duration Dual Antiplatelet Therapy in Patients Undergoing Lower Extremity Endovascular Revascularization</brief_title>
  <official_title>Evaluation of Short Versus Long Duration Dual Antiplatelet Therapy in Patients Undergoing Lower Extremity Endovascular Revascularization</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospitals Cleveland Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospitals Cleveland Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of the trial is to evaluate short versus long duration dual
      antiplatelet therapy in patients undergoing lower extremity endovascular revascularization.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>July 2016</start_date>
  <completion_date type="Anticipated">July 2020</completion_date>
  <primary_completion_date type="Anticipated">July 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Major Adverse Cardiovascular Event Rates</measure>
    <time_frame>12 months post-intervention</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Major Adverse Limb Event Rates</measure>
    <time_frame>12 months post-intervention</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Quality of Life</measure>
    <time_frame>12 Months post-intervention</time_frame>
    <description>Assessed by Intermittent Claudication Questionnaire and Short Form-36 Health Survey</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">450</enrollment>
  <condition>Peripheral Arterial Disease</condition>
  <condition>Endovascular Procedures</condition>
  <arm_group>
    <arm_group_label>Short Term</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The short term group will continue Aspirin 81mg and Clopidogrel 75mg for 1 month after the intervention. After that, they will continue Aspirin 81mg only.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Long Term</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The long term group will continue Aspirin 81mg and Clopidogrel 75mg for 6 months after the intervention. After this time, they will continue on Aspirin 81mg only.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aspirin</intervention_name>
    <arm_group_label>Short Term</arm_group_label>
    <arm_group_label>Long Term</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clopidogrel</intervention_name>
    <arm_group_label>Short Term</arm_group_label>
    <arm_group_label>Long Term</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Provide signed informed consent before initiation of any study related procedures

          2. Be at least 18 years of age

          3. Successful percutaneous lower extremity (iliac and infrainguinal) endovascular
             revascularization (percutaneous transluminal angioplasty, and /or stent).

          4. At least 1 vessel run-off in segment distal to the intervention

          5. Rutherford Classification 2-5 that is unresponsive to medical therapy

        Exclusion Criteria:

          1. Acute limb ischemia

          2. Procedure includes device deployment that has specific FDA regulations for
             anticoagulation/anti-platelet medication regimen.

          3. Patient undergoing atherectomy procedure

          4. Intervention includes deployment of drug eluted stent

          5. Critical limb ischemia (Rutherford Classification 6)

          6. Thrombocytopenia: Platelet count &lt;50k

          7. Liver disease (Childs-Pugh B or C)

          8. Existing need for on going clopidogrel therapy

          9. Proton Pump Inhibitor Use (If unable to be switched)

         10. Need for therapeutic anticoagulation

         11. Known hypercoagulable disorder

         12. Allergy or contraindication to aspirin or clopidogrel

         13. Pregnancy

         14. Patients enrolled in another investigational drug or device study within the past 30
             days
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Vikram Kashyap, MD</last_name>
    <phone>216-844-3013</phone>
    <email>vikram.kashyap@uhhospitals.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Andrew Shevitz, MA</last_name>
    <phone>216-844-7532</phone>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University Hospitals Case Medical Center</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vikram Kashyap, MD</last_name>
      <phone>216-844-7532</phone>
      <email>vikram.kashyap@uhhospitals.org</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 29, 2015</study_first_submitted>
  <study_first_submitted_qc>April 29, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 5, 2015</study_first_posted>
  <last_update_submitted>June 15, 2016</last_update_submitted>
  <last_update_submitted_qc>June 15, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 16, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Hospitals Cleveland Medical Center</investigator_affiliation>
    <investigator_full_name>Dr. Vikram S. Kashyap, M.D.</investigator_full_name>
    <investigator_title>Chief, Division of Vascular Surgery &amp; Endovascular Therapy</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Peripheral Arterial Disease</mesh_term>
    <mesh_term>Peripheral Vascular Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aspirin</mesh_term>
    <mesh_term>Clopidogrel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

